Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Half of the patients with metastatic melanoma treated with nivolumab- ipilimumab are still alive after 5 years - BJMO

Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress

Nivolumab With Ipilimumab May Negate Need for Whole Brain Radiotherapy in Melanoma With Brain Metastases - Cancer Therapy Advisor

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Cancers, Free Full-Text

Translated article] Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?

Cancers, Free Full-Text

1694-Melanoma metastatic ipilimumab and nivolumab (induction)

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma